Clinical Trial Update: Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 dose-ranging trial evaluated the safety and efficacy of OTX-101 for keratoconjunctivitis sicca (dry eye disease); the study has completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease
• Keratoconjunctivitis Sicca

Drugs mentioned

• OTX-101 (cyclosporine A 0.09% ophthalmic emulsion)

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Keratoconjunctivitis Sicca, Dry Eye Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-12-14